ARVO2020 cancelled because of Coronavirus (COVID-19)
ARVO has decided to cancel the Annual Meeting to have taken place May 1 – 7 in Baltimore, Md, USA
News
New Technologies for Outcome Measures in Uveal Melanoma
Basel Series of Special Interest Focus Groups (SIFG) - „New Technologies for Outcome Measures in Uveal Melanoma” In Collaboration with the European Ocular Oncology Group and the International Society of Ocular Oncology
Eye care is key when you're working from home
If you're one of the many people who've switched to working at home during the COVID-19 pandemic, you need to take care of your eyes, the American Academy of Ophthalmology says.
Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathy
Ocuphire Pharma announced that it has screened the first patient in ZETA-1, a phase 2 trial to evaluate APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (PDR). Effects on diabetic macular edema will be explored as a secondary outcome. A number of retinal centers across the US are active and recruiting eligible diabetic retinopathy patients.
Biden wants $6.5 billion for new health agency to speed treatments
The Biden administration began to flesh out a proposal for a new agency—modeled on the military’s Defense Advanced Research Projects Agency (DARPA)—that would seek to speed the development of medical treatments by funding risky, innovative projects. The agency, dubbed ARPA-Health (ARPA-H), would be housed at the National Institutes of Health and have a 2022 budget of $6.5 billion.
Santen Announces Global Research Initiative to Study and Develop New Treatments for Glaucoma
Santen announced a research initiative with scientists from Massachusetts Eye and Ear, and Ulster University, UK, to research and develop novel treatments for glaucoma.
UK announces €250M towards Horizon Europe participation cost following scientist revolt
Government comes up with 11th hour funds to help meet association cost after lobbying effort by science leaders. But critics still call plan ‘very opaque’, and say it isn’t enough
Alcon Canada Introduces UV Only IOLs for AcrySof IQ PanOptix and AcrySof IQ Vivity Portfolios
Alcon has announced the availability of AcrySof IQ PanOptix UV IOL, AcrySof IQ PanOptix Toric UV IOL, AcrySof IQ Vivity UV IOL, and AcrySof IQ Vivity Toric UV IOL as part of the presbyopia-correcting lens portfolio in Canada.
European Innovation Council opens €1B funding round for start-ups
Small and medium-sized companies can apply for grants of up to €2.5M and direct equity investments of up to €15M in the first calls
Biden pursues giant boost for science spending
US president’s first budget proposal emphasizes applied research and public health, and aims to tackle climate change and racial injustice.
Essilor to Present New Results for its Stellest Lens for Children With Myopia
Essilor will unveil pivotal 2-year clinical trial results of its Stellest lens for myopia. The 2-year results demonstrate that Essilor Stellest lenses slow down myopia progression by 67% on average, when compared to single vision lenses, when worn at least 12 hours a day, according to Essilor.
‘We must adapt’: EU research chief on Europe’s €100-billion funding programme
Commissioner Mariya Gabriel will oversee the implementation of the Horizon Europe scheme.
Publication of Preclinical Efficacy Results on IOP-Lowering Compounds announced
Nicox SA anounces the publication of Preclinical Efficacy Results on a new class of Non-PGA NO-Donating IOP-Lowering Compounds
Bausch + Lomb Launches Alaway Preservative Free Antihistamine Eye Drops
Bausch + Lomb announced the US launch of Alaway Preservative Free (ketotifen fumarate ophthalmic solution 0.035%) antihistamine eye drops. Bausch + Lomb says Alaway is the first and only over-the-counter (OTC) preservative-free antihistamine eye itch relief drop approved by the FDA.
Treating vision loss globally would have social and economic benefits
Written by 73 leading experts from 25 countries, The Lancet Global Health Commission Report on Global Eye Health reveals that with the right tools, strategies, and sufficient funding, improving eye health can have immediate and substantial benefits for the economic and social prosperity of individuals and nations.